Indian Journal of Pharmacology Home 

[Download PDF]
Year : 2022  |  Volume : 54  |  Issue : 2  |  Page : 150--152

Desensitization to liposomal amphotericin B after anaphylaxis in a patient with COVID-19-associated mucormycosis – A case with review of literature

Satish Swain1, Animesh Ray1, Naveet Wig1, Anjan Trikha2,  
1 Department of Medicine, All India Institute of Medical Sciences, New Delhi, India
2 Department of Anaesthesia and Critical Care, All India Institute of Medical Sciences, New Delhi, India

Correspondence Address:
Dr. Animesh Ray
Department of Medicine, All India institute of medical Sciences, New Delhi

How to cite this article:
Swain S, Ray A, Wig N, Trikha A. Desensitization to liposomal amphotericin B after anaphylaxis in a patient with COVID-19-associated mucormycosis – A case with review of literature.Indian J Pharmacol 2022;54:150-152

How to cite this URL:
Swain S, Ray A, Wig N, Trikha A. Desensitization to liposomal amphotericin B after anaphylaxis in a patient with COVID-19-associated mucormycosis – A case with review of literature. Indian J Pharmacol [serial online] 2022 [cited 2022 Jun 29 ];54:150-152
Available from:

Full Text


We present a case of COVID-associated mucormycosis (CAM) who was successfully desensitized to liposomal amphotericin B. A 57-year-old diabetic male, who had recently recovered from severe COVID-19 illness, presented to us with paresthesia, pain, and swelling over left maxillary sinus for 12 days. On examination, there was tenderness with mild erythema over the left zygomatic region. A magnetic resonance imaging of orbit and paranasal sinus showed mucosal thickening and sinus opacification suggestive of sinusitis. Subsequently, an endoscopic biopsy from left maxillary sinus was done which showed irregular, thick, nonseptate hyphae between the necrotic tissue confirming the diagnosis of left sinonasal mucormycosis. The patient was started on intravenous liposomal amphotericin B (L-AmB) (Ambisome™) at a dose of 5 mg/kg/day. Five minutes into the first dose of the drug, the patient developed shortness of breath with wheeze along with dizziness. On examination, the patient had cold clammy skin, hypotension (blood pressure of 80/60 mm Hg), tachycardia (heart rate of 120/min), and room air saturation of 86%. Amphotericin infusion was immediately stopped and the patient was administered 0.5 mg epinephrine through intramuscular route for anaphylaxis. The condition of the patient stabilized after two hours of other supportive management. The hematological and biochemical parameters of the patient were with the normal limits. Due to laboratory limitations, serum tryptase level to confirm anaphylaxis was not done. Skin hypersensitivity testing for L-AmB has not been validated in literature and hence was not performed. Hence, the diagnosis of anaphylaxis to L-AmB was made on clinical ground.

In presence of anaphylaxis to L-AmB as in our patient, the options available for the treatment of mucormycosis were to use alternative drugs (inferior in efficacy like echinocandins or with unproven efficacy like isavuconazole) or to desensitize the patient to L-AmB. After discussing with the infectious disease team, a joint decision for drug desensitization was taken. An informed consent was obtained from the patient after explaining the pros and cons for the same. He was shifted to intensive care unit where we proceeded with L-AmB desensitization under close observation; we used the same protocol used by Shadur et al. [Table 1].[1] A seven-step protocol was followed, to begin with, L-AmB concentration of 0.00004 mg/ml (volume of 10 ml, total dose 0.0004 mg) was given and then with each step, a 10-fold increase in concentration was given. There was a 2-h gap between each step and finally, a cumulative dose of 444.44 mg was given. The patient was premedicated with promethazine and no adverse reaction was noted during the entire procedure. The patient tolerated the desensitization protocol well and was successfully desensitized to L-AmB. He subsequently received 300 mg of L-AmB daily to a cumulative dose of 8 grams without any sign of adverse effects. The patient also underwent surgical debridement of sinuses for adequate source control. He is currently following up on maintenance therapy with posaconazole.{Table 1}

L-AmB is one of the indispensable drugs in the antifungal armamentarium, preferred over other antifungal agents in the treatment of mucorales, Cryptococcus, etc., in terms of both efficacy and safety. After an anaphylaxis reaction to a drug, it is generally contraindicated for re-use unless it is successfully desensitized to or an alternative drug may be used. Drug desensitization is a procedure that induces temporary tolerance to a drug by altering the immune response. There have been various mechanism postulated for it although exact mechanism is yet unknown. Possible mechanisms include (1) internalization of receptors on mast cell; (2) augmentation of regulatory cytokines (IL-10 and IL-35); (3) activation/expansion of drug-specific Tr35 cells; (4) reduction of anti-drug antibodies levels.[3]

Desensitization is usually attempted for those drugs, where there is no effective alternative and the adverse reaction is proven to be IgE mediated or clinical history is strongly suggestive of mast cell-mediated reaction. Drug desensitization is a temporary state that has to be maintained by giving the drug daily, allergic sensitivity returns back once the drug is stopped and cleared from the body. Desensitization process involves starting the drug at very low dose (1/10,000th of total dose or 1/1000th dilution of total dose) and increasing gradually until the complete recommended dose is administered. A rapid 12 step standardized desensitization protocol which was initially developed and used at Brigham and Women's Hospital and Children's Hospital Boston for penicillin and cephalosporins is now being used for other drugs too (antibiotics, chemotherapeutics agent, and monoclonal antibodies).[5]

Literature concerning desensitization of L-AmB is sparse so we carried out a literature review. We searched PubMed, Embase, and Web of Science database a using a combination of key words “amphotericin b” and “desensitization.” This search yielded 6 published reports. The first report of amphotericin B desensitization goes back to 1995. In the past decade (2011-2021), only 8 patients have been reported to be successfully desensitized to L-AmB and one to conventional AmB (deoxycholate) (six were adults, two adolescents, and one was a child). Different protocols were used as there is no standardized protocol that exists for L-AmB. Details of all the procedure have been tabulated in [Table 1]. Limitations of our report include single patient and the lack of investigations to confirm IgE antibody-mediated sensitivity reaction.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.


1Shadur B, Trahair TN, O'Brien T, Russell SJ, Ziegler JB. Desensitisation to liposomal amphotericin B. J Allergy Clin Immunol Pract 2017;5:181-3.
2Ay Y, Yilmaz D, Balkan C, Karapinar B, Midyat L, Akin M. Zygomycosis in a child with severe aplastic anemia who has invasive pulmonary aspergillosis: hypersensitivity reaction to liposomal amphotericin B and successful challenge. J Pediatr Inf 2011;5:22-5.
3Dhindsa-Castanedo L, Narra M. Desensitization to liposomal amphotericin B after anaphylactic reaction. J Allergy Clin Immunol 2012;129:AB105.
4Ravi A, Maddox D. Amphotericin-B-liposomal. React Wkly 2014;1529:33.
5Alandijani SA, Abdilahi M, Alariefy MA, Almutairi TN, Alghanemi MG. Liposomal Amphotericin B Successful Desensitization Protocol for the Treatment of Aspergillosis in Immunocompromised Woman: Case Report. Austin J Clin Immunol. 2019; 6(1):1036. Available from: https://austinpublishinggroup. com/clinical-immunology/fulltext/ajci-v6-id1036.php. [Last accessed on 2021 Jun 22].